Drug Trial Radar · NCT01666808
FACBC Outcomes for Post Prostatectomy
Last checked: Nov 20, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Sep 2012
Primary completion
Apr 18, 2022
Study completion Apr 18, 2022
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigators will perform a study with 162 patients in whom there is a strong suspicion of prostate cancer that has returned to the body after having a prostatectomy. Half of these patients will have radiotherapy decision-making and delivery per the usual routine, and half of these patients will have the radiotherapy decision and volumes guided by the FACBC test (anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (anti-3- \[18F\]FACBC). The major goal of the investigation is to see whether the FACBC improves the selection and the cancer control rates of post-surgery patients with a rising PSA who undergo radiotherapy.
Conditions
- Prostate Cancer
Interventions
FACBCDrug
FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
Radiation therapyRadiation
External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Failure-free SurvivalTime frame: 3-Year post-intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.